HK1117141A1 - Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form - Google Patents
Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph formInfo
- Publication number
- HK1117141A1 HK1117141A1 HK08105767.2A HK08105767A HK1117141A1 HK 1117141 A1 HK1117141 A1 HK 1117141A1 HK 08105767 A HK08105767 A HK 08105767A HK 1117141 A1 HK1117141 A1 HK 1117141A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preparation
- polymorph form
- new crystalline
- hemicalcium salt
- crystalline atorvastatin
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0500370A HU0500370D0 (en) | 2005-04-08 | 2005-04-08 | New crystalline atorvastatin hemicalcium polimorph |
HU0600120A HUP0600120A3 (en) | 2006-02-14 | 2006-02-14 | New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it |
PCT/HU2006/000026 WO2006106372A1 (en) | 2005-04-08 | 2006-04-07 | New crystalline atorvastatin hemicalcium salt polymorph form |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1117141A1 true HK1117141A1 (en) | 2009-01-09 |
Family
ID=89986585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08105767.2A HK1117141A1 (en) | 2005-04-08 | 2008-05-23 | Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090215855A1 (bg) |
EP (1) | EP1868993B1 (bg) |
JP (1) | JP5523699B2 (bg) |
BG (1) | BG66035B1 (bg) |
CZ (1) | CZ2007772A3 (bg) |
EA (1) | EA014079B1 (bg) |
HK (1) | HK1117141A1 (bg) |
IL (1) | IL186499A (bg) |
NO (1) | NO20075721L (bg) |
RO (1) | RO200700700A8 (bg) |
RU (1) | RU2409563C2 (bg) |
SK (1) | SK288276B6 (bg) |
WO (1) | WO2006106372A1 (bg) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100023059A (ko) | 2005-12-13 | 2010-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법 |
AU2007219107B2 (en) * | 2006-02-22 | 2012-12-06 | Mylan Laboratories Ltd. | New crystalline form of Atorvastatin hemi-calcium |
WO2011077843A1 (ja) * | 2009-12-25 | 2011-06-30 | 沢井製薬株式会社 | アトルバスタチン含有被覆製剤 |
KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
WO1997003959A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
CA2426632C (en) * | 2000-11-03 | 2008-08-05 | Teva Pharmaceutical Industries, Ltd. | Atorvastatin hemi-calcium form vii |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
ATE420070T1 (de) * | 2000-12-27 | 2009-01-15 | Teva Pharma | Kristalline formen von atorvastatin |
DE03713610T1 (de) * | 2002-02-15 | 2005-10-20 | Teva Pharma | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium |
IL163594A0 (en) * | 2002-02-19 | 2005-12-18 | Teva Pharma | Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent |
-
2006
- 2006-04-07 RU RU2007140797/04A patent/RU2409563C2/ru not_active IP Right Cessation
- 2006-04-07 JP JP2008504860A patent/JP5523699B2/ja not_active Expired - Fee Related
- 2006-04-07 SK SK5125-2007A patent/SK288276B6/sk not_active IP Right Cessation
- 2006-04-07 US US11/887,890 patent/US20090215855A1/en not_active Abandoned
- 2006-04-07 RO ROA200700700A patent/RO200700700A8/ro unknown
- 2006-04-07 WO PCT/HU2006/000026 patent/WO2006106372A1/en active Application Filing
- 2006-04-07 CZ CZ20070772A patent/CZ2007772A3/cs unknown
- 2006-04-07 EA EA200702191A patent/EA014079B1/ru not_active IP Right Cessation
- 2006-04-07 EP EP06727218.7A patent/EP1868993B1/en active Active
-
2007
- 2007-10-08 IL IL186499A patent/IL186499A/en not_active IP Right Cessation
- 2007-11-08 NO NO20075721A patent/NO20075721L/no not_active Application Discontinuation
- 2007-11-08 BG BG10109992A patent/BG66035B1/bg unknown
-
2008
- 2008-05-23 HK HK08105767.2A patent/HK1117141A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RO123642B1 (ro) | 2015-07-30 |
JP5523699B2 (ja) | 2014-06-18 |
NO20075721L (no) | 2008-01-04 |
EP1868993B1 (en) | 2014-04-30 |
EP1868993A1 (en) | 2007-12-26 |
RU2409563C2 (ru) | 2011-01-20 |
US20090215855A1 (en) | 2009-08-27 |
SK51252007A3 (sk) | 2008-07-07 |
JP2008534669A (ja) | 2008-08-28 |
BG109992A (bg) | 2008-05-30 |
IL186499A (en) | 2016-04-21 |
RO200700700A8 (ro) | 2015-07-30 |
IL186499A0 (en) | 2008-01-20 |
WO2006106372A1 (en) | 2006-10-12 |
RU2007140797A (ru) | 2009-05-20 |
EA200702191A1 (ru) | 2008-04-28 |
WO2006106372A8 (en) | 2008-03-13 |
CZ2007772A3 (cs) | 2008-02-27 |
SK288276B6 (sk) | 2015-06-02 |
EA014079B1 (ru) | 2010-08-30 |
BG66035B1 (bg) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1123682A1 (en) | Process for preparing a synthetic intermediate for preparation of branched nucleosides | |
HK1110866A1 (en) | Crystalline form of a quinolinone-carboxamide compound | |
IL185419A0 (en) | Improved process for the synthesis of enantiomeric indanylamine derivatives | |
IL192362A0 (en) | Processes for preparing intermediate compounds useful for the preparation of ezetimibe | |
IL185470A0 (en) | Novel salt of quinuclidine derivative | |
IL181868A0 (en) | Process for preparing forms of atorvastatin calcium substantially free of impurities | |
IL184715A0 (en) | Process for the preparation of intermediates | |
ZA200701016B (en) | Process for the preparation of isothiazole derivatives | |
PL1926732T3 (pl) | Sposób wytwarzania związków karbapenemu | |
EP1945614A4 (en) | PROCESS FOR THE PREPARATION OF AMLODIPINE CHIRAL GENTISATE | |
HK1117141A1 (en) | Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form | |
WO2007099552A3 (en) | Novel crystalline form of atovastatin hemi-magnesium | |
HK1105968A1 (en) | Process for production of 3-alkenylcephem compounds 3- | |
IL186294A0 (en) | A process for the preparation of phenyltetrazole compounds | |
IL191919A0 (en) | Process for preparing a crystalline form of atorvastatin hemi-calcium | |
ZA200900208B (en) | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | |
EP1853558A4 (en) | PROCESS FOR THE PRODUCTION OF ATORVASTATIN HEMICALCIUM | |
IL187981A0 (en) | Crystalline forms of a pyrrolotriazine compound | |
PT1937662E (pt) | Processo para a preparação de duloxetina | |
EP1858844A4 (en) | NEW CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | |
EP1986997A4 (en) | NEW CRYSTALLINE HEMI-CALCIUM FORM OF ATORVASTATIN | |
GB0506967D0 (en) | Novel crystalline salt | |
HK1125101A1 (en) | Solid salt forms of a pyrrole substituted 2-indolinone | |
GB0525710D0 (en) | An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds | |
GB0505861D0 (en) | Methods for the synthesis of heteroaromatic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180407 |